These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Immunization after invasive Haemophilus influenzae type b disease. Serologic response to a conjugate vaccine. Edwards KM; Decker MD; Porch CR; Palmer P; Bradley R Am J Dis Child; 1989 Jan; 143(1):31-3. PubMed ID: 2783356 [TBL] [Abstract][Full Text] [Related]
50. Haemophilus influenzae type b-specific antibody in infants after maternal immunization. Englund JA; Glezen WP; Thompson C; Anwaruddin R; Turner CS; Siber GR Pediatr Infect Dis J; 1997 Dec; 16(12):1122-30. PubMed ID: 9427456 [TBL] [Abstract][Full Text] [Related]
51. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen. Bewley KM; Schwab JG; Ballanco GA; Daum RS Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483 [TBL] [Abstract][Full Text] [Related]
52. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Hay JW; Daum RS Pediatr Infect Dis J; 1990 Apr; 9(4):246-52. PubMed ID: 2110651 [TBL] [Abstract][Full Text] [Related]
53. Selective antibody deficiency to Haemophilus influenzae type B capsular polysaccharide vaccination in children with recurrent respiratory tract infection. Herrod HG; Gross S; Insel R J Clin Immunol; 1989 Sep; 9(5):429-34. PubMed ID: 2621246 [TBL] [Abstract][Full Text] [Related]
54. Antibodies against Haemophilus influenzae type b and tetanus in infants after subcutaneous vaccination with PRP-T/diphtheria, or PRP-OMP/diphtheria-tetanus vaccines. Carlsson RM; Claesson BA; Iwarson S; Lagergård T; Käyhty H Pediatr Infect Dis J; 1994 Jan; 13(1):27-33. PubMed ID: 8170729 [TBL] [Abstract][Full Text] [Related]
55. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. Capeding MR; Nohynek H; Pascual LG; Kayhty H; Sombrero LT; Eskola J; Ruutu P Am J Trop Med Hyg; 1996 Nov; 55(5):516-20. PubMed ID: 8940983 [TBL] [Abstract][Full Text] [Related]
56. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. Black SB; Shinefield HR; Fireman B; Hiatt R J Infect Dis; 1992 Jun; 165 Suppl 1():S139-43. PubMed ID: 1588149 [TBL] [Abstract][Full Text] [Related]
57. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection. Kaplan SL; Duckett T; Mahoney DH; Kennedy LL; Dukes CM; Schaffer DM; Mason EO J Pediatr; 1992 Mar; 120(3):367-70. PubMed ID: 1538281 [TBL] [Abstract][Full Text] [Related]
58. Haemophilus influenzae b polysaccharide revaccination: a continued role for the unconjugated vaccine. Pichichero ME; Bracikowski A; Sullivan R; Madore D; Anderson P Pediatr Infect Dis J; 1989 Jan; 8(1):20-3. PubMed ID: 2784202 [TBL] [Abstract][Full Text] [Related]
59. New vaccines against Haemophilus influenzae type b. Shapiro ED Pediatr Clin North Am; 1990 Jun; 37(3):567-83. PubMed ID: 2190140 [TBL] [Abstract][Full Text] [Related]
60. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. Shapiro ED; Berg AT Pediatrics; 1990 Apr; 85(4 Pt 2):643-7. PubMed ID: 2179854 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]